PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11929332-5 2002 Treatment for 8 weeks with candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg or candesartan cilexetil 16 mg induced SBP/DBP reductions of 12.0/7.5 mm Hg and 7.5/5.5mm Hg, respectively (p < 0.05 both comparisons). candesartan 27-38 D-box binding PAR bZIP transcription factor Homo sapiens 126-129 20016523-3 2010 The objective of this analysis was to compare the efficacy of candesartan and losartan with respect to reduction in systolic and diastolic BP (SBP and DBP). candesartan 62-73 D-box binding PAR bZIP transcription factor Homo sapiens 151-154 20860416-3 2010 Therapy with candesartan cilexetil 0.05, 0.20, and 0.40 mg/kg/day for 4 weeks was effective in the treatment of hypertension in children aged 1 to <6 years, inducing significant dose-dependent reductions from baseline in sitting SBP (SSBP) [primary endpoint] and sitting DBP (SDBP) in the double-blind phase of a randomized, parallel-group, multinational, dose-ranging clinical study. candesartan 13-24 D-box binding PAR bZIP transcription factor Homo sapiens 274-277 12946547-9 2003 Significant changes from baseline to month 12 occurred with candesartan in SBP and DBP (both P < 0.01) and AER (P < 0.05). candesartan 60-71 D-box binding PAR bZIP transcription factor Homo sapiens 83-86 12946547-11 2003 When we interrupted perindopril and candesartan therapy for a 1-month washout period, changes in SBP and DBP values were significant compared with month 12 in both groups (all P < 0.05). candesartan 36-47 D-box binding PAR bZIP transcription factor Homo sapiens 105-108 19090875-3 2008 Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with candesartan and 3.7/1.8 mm Hg with placebo (P<.01 compared to placebo for SBP and for the mid and high doses for DBP; placebo-corrected 4.9/3.0-7.5/6.2 mm Hg). candesartan 83-94 D-box binding PAR bZIP transcription factor Homo sapiens 26-29